Akorn, Inc. (AKRX)
(Delayed Data from NSDQ)
$2.85 USD
+0.14 (5.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.86 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.85 USD
+0.14 (5.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.86 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Akorn (AKRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Akorn's (AKRX) fourth-quarter 2019 results are likely to reflect a decline in sales volume due to stiffening competition.
Akorn Enters Oversold Territory
by Zacks Equity Research
Akorn, Inc. (AKRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Akorn (AKRX) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Akorn (AKRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Generic Drugmakers Gain as Price-Fixing Probe Nears an End
by Indrajit Bandyopadhyay
Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Generic Drugs Industry Turns the Corner on Price Stabilization
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs are leading to recovery in the industry. New launches are also a boost. However, competition remains stiff.
The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Forterra, Barrett Business, Chuy's, Akorn and Quanex.
5 Small-Cap Stocks Outpacing the Broader Market in 2019
by Nalak Das
Despite the slow pace of movement of small-cap stock prices, a few stocks within this stable have skyrocketed ahead of the large-cap-centric indexes this year.
New Strong Buy Stocks for November 7th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Akorn (AKRX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Akorn (AKRX) delivered earnings and revenue surprises of 150.00% and 0.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Akorn (AKRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Akorn (AKRX) Rating Upgrade to Buy
by Zacks Equity Research
Akorn (AKRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Akorn (AKRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akorn (AKRX) delivered earnings and revenue surprises of 66.67% and 3.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Akorn (AKRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akorn (AKRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akorn (AKRX) delivered earnings and revenue surprises of 28.57% and 8.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Akorn (AKRX) Stock
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
Options Traders Expect Huge Moves in Akorn (AKRX) Stock
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility
by Zacks Equity Research
Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.
Do Options Traders Know Something About Akorn (AKRX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
Is Akorn (AKRX) Stock a Suitable Pick for Value Investors?
by Zacks Equity Research
Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Implied Volatility Surging for Akorn (AKRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.
Is Akorn (AKRX) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Akorn, Inc. (AKRX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AKRX vs. AMPH: Which Stock Is the Better Value Option?
Bausch (BHC) Looks Good: Stock Adds 13.9% in Session
by Zacks Equity Research
Bausch (BHC) shares rose nearly 14% in the last trading session, amid huge volumes.
Akorn Enters Oversold Territory
by Zacks Equity Research
Akorn has been on a bit of a cold streak lately.
AKRX vs. AMPH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AKRX vs. AMPH: Which Stock Is the Better Value Option?